Thursday 16 October, 2025
Objectives: Zolpidem, a common sleep inducing imidazopyridine, that has been the subject of recent regulatory dosing adjustments. This project sought…
Read morePoster: New Modelling Approaches
Using Bayesian-PBPK Modeling for Assessment of Inter-Individual Variability and Subgroup Stratification
Thursday 16 October, 2025
Objectives: To combine Bayesian statistics with detailed mechanistic physiologically-based pharmacokinetic (PBPK) models in order to provide a powerful tool to…
Read moreSimultaneous Modelling Of Fexofenadine In In Vitro Cell Culture And In Situ Experiments
Thursday 16 October, 2025
Introduction: Fexofenadine HCl (FEX), a second generation non-sedating histamine H1 receptor antagonist, is an active metabolite of terfenadine. Permeability of…
Read moreA homeostatic model for CD4 count recovery in HIV-infected children
Thursday 16 October, 2025
Objectives: A two-compartment model of CD4 memory T-cell homeostasis has already provided a compelling explanation of the slow decline in…
Read moreImplementation of a Global NONMEM Modeling Environment
Thursday 16 October, 2025
Objectives: Lilly is a global corporation with research facilities in many parts of the world, including North America, Europe, and…
Read moreEnhancing population PK modeling efficiency using an integrated workflow
Thursday 16 October, 2025
Objectives: Population pharmacokinetic (popPK) modeling outlines a very significant area of Pharmacometrics, or Modeling & Simulation. PopPK activities need to…
Read moreUsing a model-based approach to address FDA’s midcycle review concerns by demonstrating the contribution of everolimus to the efficacy of its combination with low exposure tacrolimus in liver transplantation
Thursday 16 October, 2025
Objectives: At the mid cycle review meeting, the FDA challenged the seemingly favorable results of everolimus (EVR) in combination with…
Read morePerformance of Sequential methods under Pre-clinical Study Conditions
Thursday 16 October, 2025
Objectives: To assess the performance of sequential methods simulated under typical pre-clinical-type study designs and to make a recommendation of…
Read moreOptimization of pharmacokinetics and pharmacodynamics profiles by optimal control methods. Application to a triptorelin-testosterone PD model.
Thursday 16 October, 2025
Objectives: Triptorelin is a gonadotropin-releasing hormone agonist indicated mainly for the treatment of hormone-dependent prostate cancer. Its testosterone (TST) effects…
Read moreApplication of optimal control methods to achieve multiple therapeutic objectives: Optimization of drug delivery in a mechanistic PK/PD system
Thursday 16 October, 2025
Objectives: Optimizing delivery systems targeting constant drug concentration levels in plasma represents always a challenge, especially for long periods of…
Read more